Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-04-27Clinical Trial Update: Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) [Phase 3]
Phase 3 study of sotatercept in newly diagnosed intermediate- and high-risk pulmonary arterial hypertension was terminated.
-
CLINICAL_TRIALS withdrawal · 2026-04-08Clinical Trial Update: Evaluation of the Pulmonary Vascular Reactivity Test in Patients With Pulmonary Arterial Hypertension and a Cardiac Shunt [NA]
A clinical trial evaluating the pulmonary vascular reactivity test in patients with pulmonary arterial hypertension and a congenital cardiac…
-
CLINICAL_TRIALS withdrawal · 2026-02-03Clinical Trial Update: Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH [NA]
A clinical trial investigating non-invasive measurement of cardiac output and stroke volume in pulmonary arterial hypertension and chronic t…
-
CLINICAL_TRIALS withdrawal · 2025-06-22Clinical Trial Update: Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension
This clinical trial update notes the withdrawal of a study assessing the relationship between long-term wrist actigraphy-based physical perf…
-
CLINICAL_TRIALS withdrawal · 2025-06-13Clinical Trial Update: A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) [Phase 2]
A Phase 2 study of IkT-001Pro for pulmonary arterial hypertension has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-03-30Clinical Trial Update: A Study of Macitentan in Children Below 2 Years of Age [Phase 1]
A Phase 1 pediatric trial of macitentan for pulmonary arterial hypertension in children under 2 years old has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-01-03Clinical Trial Update: TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH
The clinical trial 'Transpulmonary Estrogen Gradient and Estrogen Receptors (TYEGER)' for pulmonary arterial hypertension has been withdrawn…
-
CLINICAL_TRIALS withdrawal · 2024-10-18Clinical Trial Update: Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension [NA]
This update reports the termination of a clinical trial evaluating pulmonary artery denervation as a treatment for pulmonary arterial hypert…
-
CLINICAL_TRIALS withdrawal · 2024-08-14Clinical Trial Update: Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension [NA]
The pilot randomized trial of ambulatory exercise in pulmonary arterial hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2023-05-15Clinical Trial Update: Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease [Phase 3]
Phase 3 trial evaluating PDE5 inhibitors in single-ventricle patients with pulmonary hypertension was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2023-02-21Clinical Trial Update: Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric [Phase 3]
Phase 3 trial investigating inhaled nitric oxide in PAH patients with LTOT use was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2020-03-03Clinical Trial Update: Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain [Phase 4]
Phase 4 trial investigating hypotonic treprostinil subcutaneous infusion for control of site pain related to treprostinil; the study has bee…
-
CLINICAL_TRIALS withdrawal · 2020-01-29Clinical Trial Update: Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension [Phase 3]
Phase 3 trial investigating a bronchodilator for exertional dyspnea in pulmonary arterial hypertension was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-07-09Clinical Trial Update: Tezosentan in Pulmonary Arterial Hypertension [Phase 2]
A Phase 2 trial of tezosentan for pulmonary arterial hypertension was terminated.
-
CLINICAL_TRIALS withdrawal · 2018-05-01Clinical Trial Update: Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil [Phase 4]
Phase 4 trial evaluating sildenafil for pulmonary hypertension associated with idiopathic pulmonary fibrosis was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2018-03-06Clinical Trial Update: Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan [Phase 4]
A Phase 4 study investigating bosentan for pulmonary arterial hypertension secondary to idiopathic pulmonary fibrosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-11-01Clinical Trial Update: Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension [Phase 3]
A Phase 3 study comparing triple therapy (oral treprostinil, ambrisentan, and tadalafil) with dual therapy (ambrisentan, tadalafil, and plac…
-
CLINICAL_TRIALS withdrawal · 2017-06-09Clinical Trial Update: Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating carbon monoxide therapy for severe pulmonary arterial hypertension was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-05-09Clinical Trial Update: An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension [Phase 4]
An open-label extension study evaluating the safety of continued subcutaneous Remodulin (treprostinil) in pulmonary arterial hypertension ha…
-
CLINICAL_TRIALS withdrawal · 2017-05-09Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension [Phase 4]
A Phase 4 trial evaluating safety, tolerability, pharmacokinetics and efficacy of two different rates of subcutaneous treprostinil dose titr…
-
CLINICAL_TRIALS withdrawal · 2017-04-11Clinical Trial Update: Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH [Phase 2]
A Phase 2 trial investigating the safety of transitioning from selexipag to Remodulin and then to oral treprostinil in adults with pulmonary…
-
CLINICAL_TRIALS withdrawal · 2016-11-15Clinical Trial Update: FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan [NA]
A clinical trial evaluating FDG uptake and lung blood flow in pulmonary arterial hypertension before and after treatment with ambrisentan ha…
-
CLINICAL_TRIALS withdrawal · 2015-12-31Clinical Trial Update: Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children [Phase 1, Phase 2]
A Phase 1/2 pediatric trial evaluating beta blockers for pulmonary arterial hypertension was withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-12-02Clinical Trial Update: Evaluating Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis [NA]
A clinical trial evaluating pulmonary arterial hypertension in patients with systemic sclerosis has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2015-09-07Clinical Trial Update: Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide [Phase 3]
A Phase 3 trial evaluating acute vasodilation response to inhaled nitric oxide in pulmonary arterial hypertension has been withdrawn by the …